Found: 4
Select item for more details and to access through your institution.
E6201, an intravenous MEK1 inhibitor, achieves an exceptional response in BRAF V600E-mutated metastatic malignant melanoma with brain metastases.
- Published in:
- Investigational New Drugs, 2019, v. 37, n. 4, p. 636, doi. 10.1007/s10637-018-0668-8
- By:
- Publication type:
- Article
Correction to: Anti-tumor and anti-metastasis efficacy of E6201, a MEK1 inhibitor, in preclinical models of triple-negative breast cancer.
- Published in:
- 2019
- By:
- Publication type:
- Correction Notice
Anti-tumor and anti-metastasis efficacy of E6201, a MEK1 inhibitor, in preclinical models of triple-negative breast cancer.
- Published in:
- Breast Cancer Research & Treatment, 2019, v. 175, n. 2, p. 339, doi. 10.1007/s10549-019-05166-3
- By:
- Publication type:
- Article
Phase I study of AG2034, a targeted GARFT inhibitor, administered once every 3 weeks.
- Published in:
- 2000
- By:
- Publication type:
- journal article